Day in Court for Y12 Civil Resisters

Sort of.

The defendants in last July’s civil resistance action at the Y12 Nuclear Weapons Complex in Oak Ridge, Tennessee will have one of their days in federal court on Friday, March 4, 2011 in Knoxville.


That’s the day federal magistrate Bruce Guyton will hold hearings on the competing motions in the case. Our side is asking the judge to dismiss the case; the government is asking the judge to muzzle the defendants when they come to trial. If they have their way, the jury will not hear any testimony about nuclear weapons, about the motives of the protesters, about civil disobedience, about faith, or about most anything else.


Charles Moxley, an expert on international law and nuclear weapons, will testify at the hearing for the defense. Moxley is expected to provide the court with information on the current status of nuclear weapons in international law; after the hearing, the judge will rule on both motions.


The actual trial is scheduled for May 9.


OREPA will likely hold a media event with Dr. Moxley on Thursday, March 3. Stay tuned for details.



Resources:

Sunday Vigil at Y-12 in Oak Ridge Tennessee

Sunday Vigil

The OREPA Board has now decided that we are prepared to do a limited re-opening of the Sunday vigil to allow for slightly more participation.  We are asking anyone who wants to attend a Sunday vigil to sign up in advance—by the Thursday before. There are two ways to sign up. You can email Ralph at orep@earthlink.net or you can call him at 865 776 5050. If the five slots are already taken, we’ll ask you to wait until next week. All vigilers are expected to wear masks. Bring your own chair. Avoid physical contact and maintain an appropriate social distance in the circle of chairs. Of course, if for any reason you feel you may have been exposed to the virus or to someone with the virus, you should not attend the vigil. At this point, we are not resuming our monthly potlucks.

Learn More »
Where Should I park? vigil-map.jpg

Please Share!

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn